Sign In
Buy ASMB
$25.55
+0.330 (+1.31%)
At Close: Jul 24, 2026
Brokerages Set Assembly Biosciences, Inc. (NASDAQ:ASMB) PT at $41.75
01:12am, Saturday, 21'st Mar 2026
Assembly Biosciences, Inc. (NASDAQ: ASMB - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seven analysts that are currently covering the stock, MarketBeat Ratings reports.
Assembly Biosciences: 'Buy' On HPI Program Opt-In And HDV Candidate Development
01:55pm, Friday, 20'th Mar 2026
Assembly Biosciences, Inc. remains a Buy as Gilead licensed its HPI program, triggering a $35M payment and potential $330M in milestones. Phase 2 trials for both the HPI program (ABI-5366/1179) and HD
Assembly Biosciences (ASMB) Q4 Earnings and Revenues Top Estimates
06:20pm, Thursday, 19'th Mar 2026
Assembly Biosciences (ASMB) came out with quarterly earnings of $2.48 per share, beating the Zacks Consensus Estimate of a loss of $0.51 per share. This compares to a loss of $1.57 per share a year ag
Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights
04:05pm, Thursday, 19'th Mar 2026
– Successfully licensed helicase-primase inhibitor program for recurrent genital herpes to Gilead, including candidates ABI-5366 and ABI-1179, following positive Phase 1b interim data; development p
Assembly Biosciences (NASDAQ:ASMB) Shares Pass Above Two Hundred Day Moving Average – Here’s What Happened
02:55am, Wednesday, 11'th Mar 2026
Assembly Biosciences, Inc. (NASDAQ: ASMB - Get Free Report)'s stock price passed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $29.48 and traded
Assembly Biosciences (NASDAQ:ASMB) Stock Crosses Above 200 Day Moving Average – Here’s Why
04:33am, Saturday, 21'st Feb 2026
Assembly Biosciences, Inc. (NASDAQ: ASMB - Get Free Report)'s share price crossed above its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $28.97 and traded
Head to Head Comparison: Parnell Pharmaceuticals (OTCMKTS:PARNF) and Assembly Biosciences (NASDAQ:ASMB)
01:11am, Sunday, 08'th Feb 2026
Parnell Pharmaceuticals (OTCMKTS:PARNF - Get Free Report) and Assembly Biosciences (NASDAQ: ASMB - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two
Financial Survey: Assembly Biosciences (NASDAQ:ASMB) and Sol-Gel Technologies (NASDAQ:SLGL)
04:39am, Tuesday, 20'th Jan 2026
Sol-Gel Technologies (NASDAQ: SLGL - Get Free Report) and Assembly Biosciences (NASDAQ: ASMB - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will comp
FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (Nasdaq: ASMB), today announced Gilead has exercised its combine
Assembly Biosciences, Inc. (ASMB) Discusses Positive Interim Results for ABI-1179 and ABI-5366 in Recurrent Genital Herpes Phase 1b Studies Transcript
Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Recurrent Genital Herpes
04:05pm, Monday, 08'th Dec 2025
– 98% reduction in HSV-2 shedding rate, >99% reduction in high viral load shedding rate and 91% reduction in virologically confirmed genital lesion rate observed in 50 mg weekly oral dose of ABI-117
Assembly Biosciences, Inc. (NASDAQ:ASMB) Given Average Recommendation of “Moderate Buy” by Analysts
03:28am, Monday, 08'th Dec 2025
Shares of Assembly Biosciences, Inc. (NASDAQ: ASMB - Get Free Report) have received an average rating of "Moderate Buy" from the eight brokerages that are covering the firm, Marketbeat Ratings reports
Assembly Biosciences, Inc. (NASDAQ:ASMB) Receives $41.25 Consensus PT from Brokerages
01:19am, Sunday, 16'th Nov 2025
Assembly Biosciences, Inc. (NASDAQ: ASMB - Get Free Report) has received an average rating of "Moderate Buy" from the seven brokerages that are currently covering the company, MarketBeat Ratings repor
Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates
04:05pm, Monday, 10'th Nov 2025
– Released positive Phase 1b interim results for long-acting helicase-primase inhibitor candidate ABI-5366 showing significant reductions in viral shedding rate and genital lesion rate in recurrent
– Phase 1b data demonstrating favorable safety and tolerability profile and potent reductions in viral nucleic acids highlighted in late-breaking poster presentation – SOUTH SAN FRANCISCO, Calif.,
